Lesson plan

Lestaurtinib

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.

Back to article

Article summary

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.

Key claims

  1. date of foundation: 1987 — source: Wikipedia · confidence 0.95
  2. employees: 4000 employees — source: Wikipedia · confidence 0.95
  3. publication date: 2014 — source: Wikipedia · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the date of foundation is "1987". What evidence would count against this claim?
  3. The record states that the employees is "4000 employees". What evidence would count against this claim?
  4. The record states that the publication date is "2014". What evidence would count against this claim?
  5. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  6. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia https://en.wikipedia.org/w/index.php?oldid=1329683050

Key claims and bibliography are generated from the same tracked claims and sources as the article page.